Federal law now shields fertility treatment from state restrictions.

What it does

This bill establishes a federal statutory right for patients to receive fertility treatments (including IVF, egg freezing, and genetic testing), for doctors to provide them, for insurers to cover them, and for manufacturers to sell related drugs and devices — all without state-imposed restrictions that go beyond widely accepted medical standards. It preempts conflicting state laws and creates federal enforcement mechanisms (Attorney General suits and private lawsuits) to strike down state limitations on fertility care.

Why we flagged it

The bill's operative mechanism is a federal preemption of state fertility restrictions, coupled with a private right of action and Attorney General enforcement. It is fundamentally a rights-protection and access-expansion bill, not a market deregulation or industry carve-out.

What the text implies

• The bill's preemption is broad and tied to 'widely accepted and evidence-based medical standards of care' as defined by the American Society for Reproductive Medicine (ASRM), not by state legislatures or courts. This delegates the standard-setting function to a private professional society, which may shift power away from democratic state processes.
• The private right of action and attorney's-fees provision create strong financial incentives for litigation against states, potentially leading to federal court intervention in medical regulation that has historically been a state domain.
• The bill protects telemedicine provision of fertility treatment and counseling, which may expand access but also creates potential for regulatory arbitrage (patients and providers in restrictive states accessing services from permissive jurisdictions).
• Manufacturers of fertility drugs and devices gain a statutory right to market and distribute products without state-imposed restrictions, which may preempt state-level safety or efficacy requirements that exceed FDA standards.
• The bill does not address cost or insurance coverage mandates; it protects the right to provide and receive treatment but does not guarantee affordability or insurance reimbursement, potentially benefiting those with resources to self-pay.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people gain a federal right to access fertility treatments and to have providers deliver them without state-imposed restrictions unmoored from medical evidence. The bill protects patient choice, provider autonomy, and access to evidence-based care while preserving legitimate state health and safety regulation. State laws that impose medically unnecessary procedures, restrict telemedicine, or ban treatments aligned with professional medical standards are preempted.

Who stands to gain

• fertility clinics and IVF providers
• pharmaceutical manufacturers (fertility drugs)
• medical device manufacturers (egg retrieval, embryo storage equipment)
• telemedicine platforms offering fertility services
• health insurance issuers (if they choose to cover fertility treatment)

Named in the bill

American Society for Reproductive Medicine (ASRM), U.S. Attorney General, State governments, Health care providers (physicians, nurse practitioners, physician assistants, pharmacists), Health insurance issuers, Manufacturers of fertility drugs and devices, FDA (Food and Drug Administration), HHS (Department of Health and Human Services)

Where it stands

35 cosponsors: 33 Democrats, 2 Independents.

• Jun 11, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 11, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 12 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $719,908 in lobbying spend. A filing names 19 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Tammy Duckworth, the sponsor, reported $148,182 in PAC receipts in the 2026 cycle.

• Human Rights Campaign — $439,908 on 2 filings
• Hadassah, the Women's Zionist Organization of America, Inc. — $120,000 on 2 filings
• Massachusetts Medical Society — $90,000 on 2 filings
• American Society for Reproductive Medicine — $40,000 on 2 filings
• American Society for Reproductive Medicine (asrm) — $20,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.